Drug intelligence / Profile preview

Legutaxel

Development stage: Unknown
Lead developer: Affinity Biopharmaceutical
Modality: Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Intravenous

Overview

QHL-236 (Legutaxel) is a small molecule drug conjugate (SMDC) developed by Affinity Biopharmaceutical for the treatment of solid tumors, including gastric carcinoma. It utilizes the proprietary Tumor MicroEnvironment Activated (TMEA) platform technology to deliver a paclitaxel payload. The drug is designed to remain inactive in systemic circulation and normal tissues, selectively releasing the active paclitaxel within the tumor microenvironment. This targeted delivery mechanism is intended to reduce the systemic toxicities typically associated with conventional paclitaxel, such as myelosuppression and neurotoxicity, while maintaining or enhancing anti-tumor efficacy.

Other names: Legutaxel

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on Legutaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Legutaxel.

Explore the full profile